4-Chloro-D-phenylalanineCAS# 14091-08-8 |
- BCX 1470
Catalog No.:BCC1413
CAS No.:217099-43-9
- BCX 1470 methanesulfonate
Catalog No.:BCC1414
CAS No.:217099-44-0
- PMSF
Catalog No.:BCC1229
CAS No.:329-98-6
- Nafamostat Mesylate(FUT-175)
Catalog No.:BCC1228
CAS No.:82956-11-4
- Aprotinin
Catalog No.:BCC1220
CAS No.:9087-70-1
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 14091-08-8 | SDF | Download SDF |
| PubChem ID | 667429 | Appearance | Powder |
| Formula | C9H10ClNO2 | M.Wt | 199.63 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | 4-Chloro-D-Phe-OH | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R)-2-amino-3-(4-chlorophenyl)propanoic acid | ||
| SMILES | C1=CC(=CC=C1CC(C(=O)O)N)Cl | ||
| Standard InChIKey | NIGWMJHCCYYCSF-MRVPVSSYSA-N | ||
| Standard InChI | InChI=1S/C9H10ClNO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
4-Chloro-D-phenylalanine Dilution Calculator
4-Chloro-D-phenylalanine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.0093 mL | 25.0463 mL | 50.0927 mL | 100.1853 mL | 125.2317 mL |
| 5 mM | 1.0019 mL | 5.0093 mL | 10.0185 mL | 20.0371 mL | 25.0463 mL |
| 10 mM | 0.5009 mL | 2.5046 mL | 5.0093 mL | 10.0185 mL | 12.5232 mL |
| 50 mM | 0.1002 mL | 0.5009 mL | 1.0019 mL | 2.0037 mL | 2.5046 mL |
| 100 mM | 0.0501 mL | 0.2505 mL | 0.5009 mL | 1.0019 mL | 1.2523 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
4-Chloro-D-Phe-OH.HCl
- Aminopotentidine
Catalog No.:BCC6761
CAS No.:140873-26-3
- ICI 215,001 hydrochloride
Catalog No.:BCC5688
CAS No.:140850-02-8
- 1-Hydroxymethyl-beta-carboline glucoside
Catalog No.:BCN7026
CAS No.:1408311-12-5
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- PF 06465469
Catalog No.:BCC6268
CAS No.:1407966-77-1
- Scandine Nb-oxide
Catalog No.:BCN7504
CAS No.:140701-69-5
- 4-Aza-5androstan-1-ene- 3-one-17carboxylic acid
Catalog No.:BCC8693
CAS No.:140700-63-6
- 1-Deoxydihydroceramide-1-sulfonic acid
Catalog No.:BCC4964
CAS No.:1407-03-0
- Levatin
Catalog No.:BCN2531
CAS No.:140670-84-4
- Kadsurenin D
Catalog No.:BCN6603
CAS No.:140669-89-2
- 12-Hydroxyjasmonic acid
Catalog No.:BCN6224
CAS No.:140631-27-2
- 4-Ethylsyringol
Catalog No.:BCN3541
CAS No.:14059-92-8
- 6-Hydroxy-5,6-dehydrosugiol
Catalog No.:BCN3127
CAS No.:140923-35-9
- (2R,3S)-Chlorpheg
Catalog No.:BCC6805
CAS No.:140924-23-8
- Benzo-18-crown-6 ether
Catalog No.:BCC8850
CAS No.:14098-24-9
- Benzo-15-crown 5-ether
Catalog No.:BCC8849
CAS No.:14098-44-3
- Nerylacetate
Catalog No.:BCN3802
CAS No.:141-12-8
- Ricinoleic acid
Catalog No.:BCC8248
CAS No.:141-22-0
- 2-Aminoethanol
Catalog No.:BCN1756
CAS No.:141-43-5
- Malonic acid
Catalog No.:BCN8534
CAS No.:141-82-2
- 2-Thiouracil
Catalog No.:BCC4752
CAS No.:141-90-2
- Frangulin B
Catalog No.:BCC8175
CAS No.:14101-04-3
- Gama-Tocotrienol
Catalog No.:BCN3720
CAS No.:14101-61-2
- PACOCF3
Catalog No.:BCC7074
CAS No.:141022-99-3
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.[Pubmed:7518926]
Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7090-4.
Female athymic nude mice bearing xenografts of OV-1063 human epithelial ovarian cancer cell line were treated with potent luteinizing hormone (LH)-releasing hormone (LH-RH) antagonist SB-75 (Cetrorelix; [Ac-D-Nal(2)1, D-Phe(4 CI)2, D-Pal(3)3, D-Cit6, D-Ala10]LH-RH in which Ac-D-Nal(2) = N-acetyl-3-(2-naphthyl)-D-alanine, D-Phe(4CI) = 4-Chloro-D-phenylalanine, D-Pal(3) = 3-(3-pyridyl)-D-alanine, and D-Cit = D-Citrulline) or with the agonist [D-Trp6]LH-RH. In the first experiment, SB-75 and [D-Trp6]LH-RH were administered in the form of microcapsules releasing 60 and 25 micrograms/day, respectively. In the second study, the analogs were given by daily s.c. injections in doses of 100 micrograms/day. In both experiments, tumor growth, as measured by reduction in tumor volume, percentage change in tumor volume, tumor burden, and increase in tumor doubling time, was significantly inhibited by treatment with SB-75 but not with [D-Trp6]LH-RH. Uterine and ovarian weights were reduced and serum LH levels decreased by administration of either analog. Chronic treatment with SB-75 greatly reduced the concentration of receptors for epidermal growth factor and insulin-like growth factor I in tumor cell membranes, a phenomenon that might be related to tumor growth inhibition. It is possible that the antitumoral effects of SB-75 on OV-1063 ovarian cancers are exerted not only through the suppression of the pituitary-gonadal axis, but also directly. In view of its strong inhibitory effect on the growth of OV-1063 ovarian cancers in vivo, the potent LH-RH antagonist SB-75 might be considered for possible hormonal therapy of advanced epithelial ovarian carcinoma.
